A Phase 3, Multicenter, Vehicle-controlled, Randomized Study to Evaluate the Efficacy, Safety, and Tolerability of AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Associated Symptoms of Dry Eye Disease (DED)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 01 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AZR-MD-001 (Primary)
Indications Meibomian gland dysfunction
Focus Registrational; Therapeutic Use
Acronyms ASTRO
Sponsors Azura Ophthalmics

Most Recent Events

27 Sep 2024 Status changed from recruiting to active, no longer recruiting.
04 Jun 2024 According to an Azura Ophthalmics media release, first patient has been enrolled in this trial.
04 Jun 2024 Status changed from not yet recruiting to recruiting, according to an Azura Ophthalmics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight